Press Releases
Press Releases
March 27, 2025
AnHorn Medicines announces AH-001, a first-in-class protein degrader for androgenetic alopecia (AGA), has officially entered Phase I clinical trial in the United States. The first subject was dosed this week, marking a major milestone in the development of this innovative therapy.
November 7, 2024
AnHorn Medicines, today announced that the U.S. Food and Drug Administration (FDA) has granted Investigational New Drug (IND) clearance for AH-001 novel protein degrader program. This IND marks a significant milestone for the company, being its first regulatory achievement within just four years of its inception.
June 3, 2024
AnHorn Medicines a AI-based drug development platform focused on creating new drugs through protein degradation, has been invited to present its latest research at the NVIDIA AI Summit on June 5 in Taipei, Taiwan.
May 15, 2023
Preclinical data highlights AH-001 as potentially compelling targeted dermatology treatment options.
April 25, 2023
Company’s proprietary drug discovery platform provides unique approach to rationally design bi-functional degraders and molecular glues to have differentiated drug profiles.
July 15, 2022
After 6 months of close collaboration with our AI and drug design teams in discovery, we have advanced the drug profile...